No to abiraterone in England & Wales
Added: Friday 9 March 2012
The National Institute for Clinical Excellence (NICE) has said that it will not recommend abiraterone, a drug for men with castration-resistant metastatic prostate cancer. NICE is responsibly for analysing the cost-effectiveness of different drugs for use in the the National Health Service in England and Wales. NICE acknowledged that there is evidence to suggest that abiraterone extends overall survival, but said that cost was the main factor in its negative decision.
In order to be able to see the content from the www.medscape.com pages, please create first a free account at following link: